ArticleFrontiers in pharmacology2025

Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study.

Xu Miao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.